IOTECH publishes pre-clinical & clinical studies covering natural & therapy-induced innate & adaptive immune responses against solid/haematological cancers
Joined September 2021
- Tweets137
- Following156
- Followers359
- Likes146
Pinned Tweet
IOTECH is the newest @myESMO #OpenAccess journal. We aim to publish the highest quality #immunooncology research and aspire to provide a forum for leaders in the IO field. Led by EIC @HaanenJohn, we look forward to receiving your research manuscripts.
youtu.be/WxTr1pyBGjE
ESMO IOTECH retweeted
The impact of #GutMicrobiota on #immunotherapy response and resistance has been established, but studies presented at #ESMOImmuno24 highlight important associations between microbiota and immunotherapy-related toxicities.
#ESMODailyReporter
📌ow.ly/SPtC50Up9u8
ESMO IOTECH retweeted
#ESMOImmuno24: According to the 2024 ESMO Immuno-Oncology Awardee, @Schumacher_lab, tackling the T-cell receptor challenge w/ vast datasets and cutting-edge high-throughput methods may pave the way for advances in #immunotherapy.
#ESMODailyReporter
📌ow.ly/rZUO50Up0BE
It's finally here! #ESMOImmuno24
📚 Delighted that all accepted abstracts, including late-breaking abstracts, will be published online in the 'ESMO Immuno-Oncology Congress 2024 Abstract Book', a supplement to @esmo_iotech.
📣 #ESMOImmuno24: J. Haanen, J. Naidoo, K. Harrington and A. di Giacomo highlight the benefits of sharing your research at this event.
⏰ Deadline: 1 October
📅 Dates: 11-13 December 2024
📍 Location: Geneva, Switzerland
🔗 Submit your abstract: ow.ly/YPwS50T1Yok
ESMO IOTECH retweeted
.@Schumacher_lab was bestowed the 2024 ESMO Award for Immuno-Oncology. He will deliver his award lecture on Wednesday, 11 December 2024 at the opening session of #ESMOImmuno24.
📌ow.ly/FiiN50U0iab
ESMO IOTECH retweeted
#ESMOImmuno24: Real-world evidence has a place in #CancerImmunotherapy. However, some challenges still limit its implementation in #ClinicalPractice. #ESMODailyReporter #ESMO-GROW
@DoniaMarco
📌ow.ly/rwXC50UoUCo
Welcome to Geneva 🇨🇭 for the much awaited #ESMOImmuno24!
💡 Presenting your work at #ESMOImmuno24? Looking for a home for your research work?
Consider submitting to @esmo_iotech:
🔗 esmoiotech.org
📢 Check out this original article by Konïg & colleagues @UniBasel_en @UniSpitalBasel 🇨🇭.
💉 BaseTIL trial: A single-center investigator-initiated phase I study of TILs + nivolumab in patients with advanced melanoma.
Available #OpenAccess 👇
esmoiotech.org/article/S2590…
📢 Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet 🇩🇰🇫🇮.
💉Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.
Available #OpenAccess 👇esmoiotech.org/article/S2590…
📢 Check out this latest original article by @TGruijl & team @amsterdamumc.
🧫An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy.
Available #OpenAccess 👇
esmoiotech.org/article/S2590…
📢 Check out this latest original article by Yeghaian, @S_Trebeschi + colleagues 🇳🇱🇨🇭🇩🇰.
🔬 Integrated noninvasive dx for prediction of survival in immunotherapy: Longitudinal CT, blood tests & clinical parameters ▶️ AI models.
Available #OpenAccess 👇
esmoiotech.org/article/S2590…
📢 Hear first hand from our Editor-in-Chief Prof @HaanenJohn about ESMO IOTECH - @myESMO’s peer-reviewed open-access specialised journal dedicated to publishing advances in immuno-oncology and technology 👇
This Post is from an account that no longer exists. Learn more
💡 Presenting your work at #ESMO24 in Barcelona 🇪🇸? Looking for a home for your research work?
Consider submitting to @esmo_iotech 👇
🔗 esmoiotech.org
ESMO IOTECH retweeted
#ESMO24: Do not miss the latest #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation.
📌 ow.ly/PgWM50Th6Q3
📢 Check out this latest original article by van Duin & colleagues - a multicentre study 🇳🇱.
🔬 Investigating association between TIL abundance in pre-tx primary/metastasis & development of severe irAEs in advanced melanoma.
Available #OpenAccess 👇
esmoiotech.org/article/S2590…
🔖 Latest REVIEW by Olivera & @DrIgMelero + colleagues on 'Regional and intratumoral adoptive T-cell therapy'.
Available #OpenAccess 👇
esmoiotech.org/article/S2590…
Congratulations to our ESMO IOTECH's Editor-in-Chief @HaanenJohn for the 2024 ESMO Lifetime Achievement Award 🏅. Well-deserved distinction, and we are all so delighted! #ESMO24 @myESMO
#ESMO24: ESMO has announced the recipients of the 2024 ESMO Society Awards in recognition of their work in strengthening the oncology field and supporting fellow oncologists in their professional careers.
📌ow.ly/Kopk50SRQUk
📚 There's still time to submit your work to this ESMO IOTECH Special Issue on 'Developments in Cell Therapy', with guest editors: @alena_grosvidal & @sklobuch.
For further details, please check out: spkl.io/60164sUYj
🚨 SPECIAL ISSUE: Developments in Cell Therapy 🚨
⏰ Submit an original article/review by 1 July 2024
📈 2022 CiteScore: 5.5
🔖 Indexed on PMC & PubMed @NLM_NIH: 'Immunooncol Technol'
Further details: spkl.io/60164sUYj
Guest editors: @alena_grosvidal & @sklobuch
📢 Check out this latest original article by @CostaSvedman & colleagues @KarolinskaUnsju
@KarolinskaInst.
🏥 Effect of glucocorticoids for the management of irAEs on outcome in IO-treated melanoma patients.
Available #OpenAccess👇
esmoiotech.org/article/S2590…
📑 Presenting your work at #ASCO24 in Chicago 🇺🇸?
Looking for a home for your research work?
Consider submitting to @esmo_iotech 👇
esmoiotech.org
ESMO IOTECH retweeted
IOTECH aspires to provide a forum for today's leaders in the field of #ImmunoOncology.
We welcome:
➡️pre-clinical/clinical studies
➡️solid/haematological cancers
➡️technological advances that decipher & improve clinical outcomes
Get in touch today!
